MedTrace Logo

Spasmodic Dysphonia Pain

NCT04648891 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-05-23

Study results available
· View outcomes & findings →

Summary

This study aims to identify adjuvant methods to improve patient comfort during in-office laryngology procedures.

Conditions

  • Spasmodic Dysphonia

Interventions

DRUG

Lidocaine

Subcutaneous injection 0.5cc 2% in 1:100,000 epinephrine

DEVICE

Vibrating wand

a vibrating instrument held adjacent to the cricothyroid space

Sponsors & Collaborators

Principal Investigators

  • David Lott, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2023-07-01
Completion
2023-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04648891 on ClinicalTrials.gov